This article is more than 5 years old. Information may no longer be current.

Salient Surgical Technologies receives FDA clearance for Aquamantys bipolar sealer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Salient Surgical Technologies Inc. announced in a press release that is has received 510(k) clearance from the FDA to use the AQUAMANTYS bipolar sealer in blunt dissection. The company also recently received Japanese regulatory approval and European CE Mark clearance for commercial marketing of the device.

According to the release, the device runs on Salient’s bipolar technology platform, using TRANSCOLLATION technology to enable surgeons to prevent and stop bleeding of soft tissue and bone during surgery. The new disposable sealer features cone-shaped electrodes that are designed to aid blunt dissection and provide hemostatic sealing across broad plains of tissue.

“We’ve incorporated Salient’s technology into our practice as a result of its proven ability to help reduce blood loss and transfusion rates,” T. Clark Gamblin, MD, MS, chief of the Division of Surgical Oncology at the Medical College of Wisconsin, stated in the release. “In our experience, the new AQUAMANTYS bipolar sealer provides a safe and convenient means to achieve these clinical benefits during surgical oncology procedures such as liver resections.”